Suppr超能文献

胶质瘤微环境产生的CCL2对于调节性T细胞和髓源性抑制细胞的募集至关重要。

CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.

作者信息

Chang Alan L, Miska Jason, Wainwright Derek A, Dey Mahua, Rivetta Claudia V, Yu Dou, Kanojia Deepak, Pituch Katarzyna C, Qiao Jian, Pytel Peter, Han Yu, Wu Meijing, Zhang Lingjiao, Horbinski Craig M, Ahmed Atique U, Lesniak Maciej S

机构信息

Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Committee on Cancer Biology, The University of Chicago, Chicago, Illinois.

Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

出版信息

Cancer Res. 2016 Oct 1;76(19):5671-5682. doi: 10.1158/0008-5472.CAN-16-0144. Epub 2016 Aug 16.

Abstract

In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). However, the mechanistic details of how Tregs and MDSCs are recruited in various tumors are not yet well understood. Here we report that macrophages and microglia within the glioma microenvironment produce CCL2, a chemokine that is critical for recruiting both CCR4 Treg and CCR2Ly-6C monocytic MDSCs in this disease setting. In murine gliomas, we established novel roles for tumor-derived CCL20 and osteoprotegerin in inducing CCL2 production from macrophages and microglia. Tumors grown in CCL2-deficient mice failed to maximally accrue Tregs and monocytic MDSCs. In mixed-bone marrow chimera assays, we found that CCR4-deficient Treg and CCR2-deficient monocytic MDSCs were defective in glioma accumulation. Furthermore, administration of a small-molecule antagonist of CCR4 improved median survival in the model. In clinical specimens of glioblastoma multiforme, elevated levels of CCL2 expression correlated with reduced overall survival of patients. Finally, we found that CD163-positive infiltrating macrophages were a major source of CCL2 in glioblastoma multiforme patients. Collectively, our findings show how glioma cells influence the tumor microenvironment to recruit potent effectors of immunosuppression that drive progression. Cancer Res; 76(19); 5671-82. ©2016 AACR.

摘要

在许多侵袭性癌症中,如多形性胶质母细胞瘤,调节性T细胞(Treg)和髓源性抑制细胞(MDSC)的积累所驱动的局部免疫抑制促进了肿瘤进展。然而,Treg和MDSC在各种肿瘤中被招募的机制细节尚未完全清楚。在此我们报告,胶质瘤微环境中的巨噬细胞和小胶质细胞产生CCL2,一种趋化因子,在这种疾病背景下,它对于招募CCR4 Treg和CCR2Ly-6C单核MDSC至关重要。在小鼠胶质瘤中,我们确定了肿瘤来源的CCL20和骨保护素在诱导巨噬细胞和小胶质细胞产生CCL2方面的新作用。在CCL2缺陷小鼠中生长的肿瘤无法最大限度地积累Treg和单核MDSC。在混合骨髓嵌合体试验中,我们发现CCR4缺陷的Treg和CCR2缺陷的单核MDSC在胶质瘤积累方面存在缺陷。此外,给予CCR4的小分子拮抗剂可提高该模型的中位生存期。在多形性胶质母细胞瘤的临床标本中,CCL2表达水平升高与患者总生存期缩短相关。最后,我们发现CD163阳性浸润巨噬细胞是多形性胶质母细胞瘤患者CCL2的主要来源。总的来说,我们的研究结果表明胶质瘤细胞如何影响肿瘤微环境以招募驱动肿瘤进展的强效免疫抑制效应细胞。《癌症研究》;76(19);5671 - 82。©2016美国癌症研究协会。

相似文献

1
CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
Cancer Res. 2016 Oct 1;76(19):5671-5682. doi: 10.1158/0008-5472.CAN-16-0144. Epub 2016 Aug 16.
3
The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues.
J Neurooncol. 2024 Sep;169(3):647-658. doi: 10.1007/s11060-024-04766-4. Epub 2024 Jul 24.
4
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1129-1138. doi: 10.1073/pnas.1910856117. Epub 2019 Dec 26.
5
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Cancer Immunol Immunother. 2008 Jan;57(1):123-31. doi: 10.1007/s00262-007-0336-x. Epub 2007 May 24.
7
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
Cancer Res. 2017 Apr 1;77(7):1599-1610. doi: 10.1158/0008-5472.CAN-16-1755. Epub 2017 Feb 15.
10
FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling.
Cancer Res. 2016 Jul 15;76(14):4124-35. doi: 10.1158/0008-5472.CAN-15-2973. Epub 2016 May 23.

引用本文的文献

1
CAR T cell therapy for central nervous system solid tumors: current progress and future directions.
Front Immunol. 2025 Aug 15;16:1600403. doi: 10.3389/fimmu.2025.1600403. eCollection 2025.
2
Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target.
Front Immunol. 2025 Jul 23;16:1627161. doi: 10.3389/fimmu.2025.1627161. eCollection 2025.
3
Development of therapeutic cancer vaccines based on cancer immunity cycle.
Front Med. 2025 Jul 14. doi: 10.1007/s11684-025-1134-6.
5
Xenoline-polarized macrophages as an alternative in vitro model of tumor-associated macrophages in glioblastoma.
Acta Neuropathol Commun. 2025 Jun 28;13(1):137. doi: 10.1186/s40478-025-02057-1.
9
The Basis for Targeting the Tumor Macrophage Compartment in Glioblastoma Immunotherapy.
Cancers (Basel). 2025 May 12;17(10):1631. doi: 10.3390/cancers17101631.

本文引用的文献

2
3
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.
J Clin Invest. 2015 Nov 2;125(11):4063-76. doi: 10.1172/JCI82152. Epub 2015 Sep 28.
4
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.
Front Oncol. 2015 Jul 6;5:153. doi: 10.3389/fonc.2015.00153. eCollection 2015.
5
CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function.
Cell Rep. 2015 Jul 14;12(2):244-57. doi: 10.1016/j.celrep.2015.06.024. Epub 2015 Jul 2.
8
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.
Neuro Oncol. 2015 Jun;17(6):801-9. doi: 10.1093/neuonc/nou363. Epub 2015 Jan 24.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验